Management of Diabetes Mellitus, Risk Factors and Complications
Main Article Content
Abstract
Chronic progressive metabolic problem and chronic hyperglycemia caused by a dysregulation of protein, lipid, and carbohydrate metabolism are two symptoms of diabetes mellitus, a complicated condition. Verapamil belongs to a group of calcium channel blockers that are not dihydropyridines. It works by preventing calcium from entering beta cells' cytoplasm, preventing the second phase of insulin release driven by glucose, as well as sulfonylurea and glucagon. Nephropathy, neuropathy, and retinopathy are examples of microvascular consequences of diabetes mellitus (cardiovascular and cerebrovascular disease). In both kinds of diabetes mellitus, higher urine albumin excretion (proteinuria) or decreased kidney glomerular filtration rate are symptoms of diabetic nephropathy, a microvascular consequence. By lowering patients' blood sugar levels and reducing their risk of cardiovascular disease, diabetes mellitus therapy aims to reduce mortality, delay the onset of disease complications, and slow the disease's progression. Metformin increases peripheral glucose utilization, liver, muscle, and adipose tissue sensitivity to insulin, inhibits gluconeogenesis, and reduces glucose absorption from the gastrointestinal system.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Bereda G, Bereda G (2021) The Incidence and Predictors of Poor Glycemic Control among Adults with Type 2 Diabetes Mellitus in Ambulatory Clinic of Mettu Karl Referral Hospital, Southwestern, Ethiopia: A Prospective Cross-Sectional Study. Int Arch Endocrinol Clin Res 7: 1-9.
II. Romaguera R, Pablo Salinas, Josep Gomez L, Salvatore Brugaletta, Antonio Gómez M, et al. (2022) Amphilimus-vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. European Heart Journal 43(13): 1320-1330.
III. Saeedi P, Petersohn I, Salpea P, Belma Malanda, Suvi Karuranga, et al. (2019) IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th (Edn). Diabetes Res Clin Pract 157: 107843.
IV. Carr AC, Spencer E, Heenan H, Lunt H, Vollebregt M, et al. (2022) Vitamin C Status in People with Types 1 and 2 Diabetes Mellitus and Varying Degrees of Renal Dysfunction: Relationship to Body Weight. Antioxidants 11(2): 245.
V. Bereda G (2021) Brief overview of diabetes mellitus. Diabetes Manag 11(S1): 21-27.
VI. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, et al. (2020) Epidemiology of type 2 diabetes-Global burden of disease and forecasted trends. J Epidemiol Glob Health 10(1): 107-111.
VII. Liu J, Ren ZH, Qiang H, Wu J, Shen M, et al. (2020) Trends in the incidence of diabetes mellitus: Results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health 20(1): 1415.
VIII. Zheng JS, Sharp SJ, Imamura F, Chowdhury R, Gundersen TE, et al. (2020) Association of plasma biomarkers of fruit and vegetable intake with incident type 2 diabetes: EPIC-InterAct case-cohort study in eight European countries. BMJ 370: 2194.
IX. Luc K, Schramm Luc A, Guzik TJ, Mikolajczyk TP (2019) Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol 70(6): 809-824.
X. Bereda G (2022) Complication of Diabetes Mellitus: Microvascular and Macrovascular Complications. Int J Diabetes 3(1): 123-128.
XI. Subramanian VS, Sabui S, Subramenium GA, Marchant JS, Said HM, (2018) Tumor Necrosis Factor alpha (TNF-alpha) reduces intestinal vitamin C uptake: A role for NF-kappaB mediated signaling. Am J Physiol Gastrointest Liver Physiol 315(2): 241-248.
XII. Bereda (2022) Risk Factors and Pathogenesis of Diabetic Nephropathy. Int J Diabetes Metab Disord 7(1): 05-07.
XIII. Bereda G (2022) Oral Antidiabetic Medications: Technical Notes. Journal of Diabetic Nephropathy and Diabetes Management 2(1): 1-10.
XIV. Gillett M, Royle P, Snaith A, Scotland G, Poobalan A, et al. (2012) Nonpharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technol Assess 16(33): 1-236.
XV. Bereda G (2022) Risk Factors, Classifications and Pathogenesis of +Diabetic Retinopathy. J Diabetes Clin Prac 5: 149.
XVI. Saha S (2022) Comparative effectiveness of adjunct non-pharmacological interventions on maternal and neonatal outcomes in gestational diabetes mellitus patients: A systematic review and network meta-analysis protocol of randomized controlled trials. Plos One 17(1): 0263336.
XVII. Parameswaran GW, Ray D (2022) Sleep, circadian rhythms, and type 2 diabetes mellitus. Clinical Endocrinology 96(1): 12-20.
XVIII. Bereda G Hyperosmolar Hyperglycemic State: Background, Precipitating Factors, Pathophysiology and Management. In J Dia It Compl pp.1-101.
XIX. Abdelghani M, Md G Hamed, Amira Said, Eman Fouad, (2022) Evaluation of perceived fears of COVID 19 virus infection and its relationship to health-related quality of life among patients with diabetes mellitus in Egypt during pandemic: a developing country single center study. Diabetology International 13(1): 108-116.
XX. Bereda G (2022) Role of Insulin: Perspectives. J Diabetes Islet Biol 5(1): 1-6.
XXI. Vasiljevic J, Torkko JM, Knoch KP, Solimena M, (2020) The making of insulin in health and disease. Diabetologia 63(10): 1981-1989.